Long acting GLP-1 receptor agonist (injectable)
Ecnoglutide 0.8 mg injection once weekly
ECNO_SC_0p8MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.31 (-2.03 to -0.45) | 0.58 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.41 (0.01 to 17.67) | 0.64 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.41 (0.01 to 16.07) | 0.71 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.74 (0.52 to 18.13) | 0.47 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.29 (0.00 to 9.28) | 0.82 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.84 (0.29 to 12.42) | 0.45 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.40 (0.25 to 8.27) | 0.52 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.85 (0.05 to 13.64) | 0.47 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.65 (0.01 to 47.83) | 0.57 |